Latest Insider Transactions at An2 Therapeutics, Inc. (ANTX)
This section provides a real-time view of insider transactions for An2 Therapeutics, Inc. (ANTX). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of AN2 Therapeutics, Inc. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of AN2 Therapeutics, Inc.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Aug 14
2024
|
Braden Michael Leonard |
BUY
Open market or private purchase
|
Indirect |
1,500,000
+20.69%
|
$1,500,000
$1.04 P/Share
|
|
Aug 09
2024
|
Ra Capital Management, L.P. |
SELL
Open market or private sale
|
Indirect |
3,525,094
-47.01%
|
$3,525,094
$1.08 P/Share
|
|
Jul 10
2024
|
Joshua M Eizen Chief Legal Officer |
BUY
Grant, award, or other acquisition
|
Direct |
60,000
+38.75%
|
-
|
|
Mar 15
2024
|
Eric Easom Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
99,000
+49.47%
|
-
|
|
Mar 15
2024
|
Paul Eckburg Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
30,000
+36.85%
|
-
|
|
Mar 15
2024
|
Sanjay Chanda Chief Development Officer |
BUY
Grant, award, or other acquisition
|
Direct |
27,500
+49.34%
|
-
|
|
Mar 15
2024
|
Kevin Michael Krause Chief Strategy Officer |
BUY
Grant, award, or other acquisition
|
Direct |
30,000
+48.45%
|
-
|
|
Mar 15
2024
|
Joshua M Eizen Chief Legal Officer |
BUY
Grant, award, or other acquisition
|
Direct |
30,000
+48.04%
|
-
|
|
Mar 15
2024
|
Lucy Day Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
27,500
+47.31%
|
-
|
|
Jan 18
2024
|
Joseph S Zakrzewski |
SELL
Open market or private sale
|
Indirect |
100,000
-19.77%
|
$1,900,000
$19.11 P/Share
|
|
Jan 16
2024
|
Adjuvant Global Health Technology Fund, L.P. |
SELL
Open market or private sale
|
Indirect |
15,907
-4.04%
|
$302,233
$19.65 P/Share
|
|
Jan 16
2024
|
Adjuvant Global Health Technology Fund, L.P. |
SELL
Open market or private sale
|
Direct |
84,093
-4.04%
|
$1,597,767
$19.65 P/Share
|
|
Jan 16
2024
|
Kabeer Aziz |
SELL
Open market or private sale
|
Indirect |
100,000
-4.04%
|
$1,900,000
$19.65 P/Share
|
|
Jan 12
2024
|
Robin Shane Readnour |
SELL
Open market or private sale
|
Indirect |
1,425
-0.16%
|
$29,925
$21.92 P/Share
|
|
Jan 10
2024
|
Robin Shane Readnour |
SELL
Open market or private sale
|
Indirect |
3,669
-0.41%
|
$77,049
$21.93 P/Share
|
|
Jan 09
2024
|
Kevin Michael Krause Chief Strategy Officer |
SELL
Open market or private sale
|
Direct |
7,417
-79.49%
|
$148,340
$20.14 P/Share
|
|
Jan 09
2024
|
Kevin Michael Krause Chief Strategy Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
7,417
+35.35%
|
$22,251
$3.51 P/Share
|
|
Jan 02
2024
|
Eric Easom Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
2,777
-56.59%
|
$55,540
$20.09 P/Share
|
|
Jan 02
2024
|
Kevin Michael Krause Chief Strategy Officer |
SELL
Open market or private sale
|
Direct |
2,583
-57.44%
|
$51,660
$20.12 P/Share
|
|
Jan 02
2024
|
Kevin Michael Krause Chief Strategy Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
2,583
+36.48%
|
$0
$0.42 P/Share
|
|
Nov 14
2023
|
Adjuvant Global Health Technology Fund, L.P. |
SELL
Open market or private sale
|
Indirect |
288
-0.07%
|
$4,608
$16.15 P/Share
|
|
Nov 14
2023
|
Adjuvant Global Health Technology Fund, L.P. |
SELL
Open market or private sale
|
Direct |
1,522
-0.07%
|
$24,352
$16.15 P/Share
|
|
Nov 14
2023
|
Kabeer Aziz |
SELL
Open market or private sale
|
Indirect |
1,810
-0.07%
|
$28,960
$16.15 P/Share
|
|
Oct 02
2023
|
Kabeer Aziz |
SELL
Open market or private sale
|
Indirect |
5,672
-0.23%
|
$90,752
$16.07 P/Share
|
|
Oct 02
2023
|
Adjuvant Global Health Technology Fund, L.P. |
SELL
Open market or private sale
|
Indirect |
902
-0.23%
|
$14,432
$16.07 P/Share
|
|
Oct 02
2023
|
Adjuvant Global Health Technology Fund, L.P. |
SELL
Open market or private sale
|
Direct |
4,770
-0.23%
|
$76,320
$16.07 P/Share
|
|
Sep 29
2023
|
Kabeer Aziz |
SELL
Open market or private sale
|
Indirect |
99,101
-3.84%
|
$1,585,616
$16.28 P/Share
|
|
Sep 29
2023
|
Adjuvant Global Health Technology Fund, L.P. |
SELL
Open market or private sale
|
Indirect |
15,764
-3.84%
|
$252,224
$16.28 P/Share
|
|
Sep 29
2023
|
Adjuvant Global Health Technology Fund, L.P. |
SELL
Open market or private sale
|
Direct |
83,337
-3.84%
|
$1,333,392
$16.28 P/Share
|
|
Sep 28
2023
|
Kabeer Aziz |
SELL
Open market or private sale
|
Indirect |
8,516
-0.33%
|
$136,256
$16.11 P/Share
|
|
Sep 28
2023
|
Adjuvant Global Health Technology Fund, L.P. |
SELL
Open market or private sale
|
Indirect |
1,356
-0.33%
|
$21,696
$16.11 P/Share
|
|
Sep 28
2023
|
Adjuvant Global Health Technology Fund, L.P. |
SELL
Open market or private sale
|
Direct |
7,160
-0.33%
|
$114,560
$16.11 P/Share
|
|
Sep 27
2023
|
Kabeer Aziz |
SELL
Open market or private sale
|
Indirect |
841
-0.03%
|
$13,456
$16.07 P/Share
|
|
Sep 27
2023
|
Adjuvant Global Health Technology Fund, L.P. |
SELL
Open market or private sale
|
Indirect |
134
-0.03%
|
$2,144
$16.07 P/Share
|
|
Sep 27
2023
|
Adjuvant Global Health Technology Fund, L.P. |
SELL
Open market or private sale
|
Direct |
707
-0.03%
|
$11,312
$16.07 P/Share
|
|
Sep 13
2023
|
Kabeer Aziz |
SELL
Open market or private sale
|
Indirect |
400
-0.02%
|
$6,400
$16.0 P/Share
|
|
Sep 13
2023
|
Adjuvant Global Health Technology Fund, L.P. |
SELL
Open market or private sale
|
Indirect |
64
-0.02%
|
$1,024
$16.0 P/Share
|
|
Sep 13
2023
|
Adjuvant Global Health Technology Fund, L.P. |
SELL
Open market or private sale
|
Direct |
336
-0.02%
|
$5,376
$16.0 P/Share
|
|
Sep 07
2023
|
Adjuvant Global Health Technology Fund, L.P. |
SELL
Open market or private sale
|
Indirect |
537
-0.13%
|
$8,592
$16.05 P/Share
|
|
Sep 07
2023
|
Adjuvant Global Health Technology Fund, L.P. |
SELL
Open market or private sale
|
Direct |
2,841
-0.13%
|
$45,456
$16.05 P/Share
|
|
Sep 07
2023
|
Kabeer Aziz |
SELL
Open market or private sale
|
Indirect |
3,378
-0.13%
|
$54,048
$16.05 P/Share
|
|
Sep 06
2023
|
Adjuvant Global Health Technology Fund, L.P. |
SELL
Open market or private sale
|
Indirect |
598
-0.14%
|
$9,568
$16.02 P/Share
|
|
Sep 06
2023
|
Adjuvant Global Health Technology Fund, L.P. |
SELL
Open market or private sale
|
Direct |
3,164
-0.14%
|
$50,624
$16.02 P/Share
|
|
Sep 06
2023
|
Kabeer Aziz |
SELL
Open market or private sale
|
Indirect |
3,762
-0.14%
|
$60,192
$16.02 P/Share
|
|
Aug 23
2023
|
Kabeer Aziz |
SELL
Open market or private sale
|
Indirect |
400
-0.02%
|
$6,400
$16.0 P/Share
|
|
Aug 23
2023
|
Adjuvant Global Health Technology Fund, L.P. |
SELL
Open market or private sale
|
Indirect |
64
-0.02%
|
$1,024
$16.0 P/Share
|
|
Aug 23
2023
|
Adjuvant Global Health Technology Fund, L.P. |
SELL
Open market or private sale
|
Direct |
336
-0.02%
|
$5,376
$16.0 P/Share
|
|
Aug 18
2023
|
Ra Capital Management, L.P. |
BUY
Open market or private purchase
|
Indirect |
1,777,778
+25.71%
|
$16,000,002
$9.0 P/Share
|
|
May 15
2023
|
Eric Easom Chief Executive Officer |
BUY
Open market or private purchase
|
Indirect |
10,000
+0.97%
|
$50,000
$5.38 P/Share
|
|
Nov 14
2022
|
Eric Easom Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
23
-0.47%
|
$345
$15.04 P/Share
|